Geron Corporation
Financials
Valuation Metrics
Geron Corporation's Market Cap is $847M. At end of 2025 it was $881M. Ranked #2555 of 3,121 in US market (top 82%), #1069 of 1,463 on NASDAQ (top 73%), #199 of 266 in Pharmaceuticals, Biotechnology & Life Sciences (top 75%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $847M | US#2,555/3,121 Sec#199/266 |
| Revenue | $205M | US#2,575/3,121 Sec#110/266 |
| Net Income | $-70M | US—/3,121 Sec—/266 |
| Total Assets | $519M | US#2,758/3,121 Sec#164/266 |
| Net Assets | $219M | US#2,657/3,121 Sec#184/266 |
| Employees | 258 | US#2,452/3,121 Sec#121/266 |
| Value | ||
| P/B | 3.87x | US#1,991/3,121 Sec#113/266 |
| P/S | 4.14x | US#2,118/3,121 Sec#64/266 |
| FCF Yield | -13.56% | US—/3,121 Sec—/266 |
| Profitability | ||
| ROE | -31.97% | US#2,580/3,121 Sec#116/266 |
| ROA | -13.47% | US#2,719/3,121 Sec#111/266 |
| Op. Margin | -18.29% | US#2,596/3,121 Sec#100/266 |
| Revenue Growth | 24.39% | US#553/3,121 Sec#68/266 |
| Financial Health | ||
| Debt Ratio | 137.41% | US#1,409/3,121 Sec#182/266 |
| Total Debt | $122M | US#2,386/3,121 Sec#109/266 |
| FCF | $-115M | US#2,657/3,121 Sec#155/266 |
| Cash | $63M | US#2,482/3,121 Sec#214/266 |
| Current Ratio | 6.92x | US#362/3,121 Sec#114/266 |
| Performance | ||
| 1Y Return | 3.94% | US#1,676/3,121 Sec#178/266 |
| 1M Return | -13.73% | US#2,737/3,121 Sec#210/266 |
| From 52W High | -34.33% | US#2,275/3,121 Sec#176/266 |
| 1Y MDD | -43.59% | US#2,188/3,121 Sec#155/266 |
| Trading | ||
| Volume | 6,147,660 shares | US#264/3,121 Sec#19/266 |
| Trading Value | $8M | US#2,452/3,121 Sec#206/266 |
| Per Share | ||
| EPS | $-0.11 | US—/3,121 Sec—/266 |
| BPS | $0.34 | US#2,780/3,121 Sec#225/266 |
Company Info
Geron Corporation is an advanced-stage biopharmaceutical company dedicated to the creation and market introduction of treatments for myeloid blood cancers. Its primary drug candidate, imetelstat, is a telomerase inhibitor currently undergoing Phase 3 clinical evaluation. This therapy aims to suppress the unchecked proliferation of cancerous stem and progenitor cells characteristic of myeloid hematologic malignancies. Imetelstat is being developed to address low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. Established in 1990, Geron's corporate headquarters are located in Foster City, California.